According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its conclusion on an analysis of four studies evaluating remdesivir’s influence on mortality from COVID-19. However, new data from US-based ACTT-1 trial does support savings on insurer payment for hospital services related to COVID. As a result of these new data from the ACTT-1 trial and remdesivir’s expanded label to include less severely ill patients, ICER is suggesting a health-benefit price benchmark of $2,470 for hospitalized patients with moderate-to-severe disease, and $70 for patients hospitalized with milder disease. Download the full ICER report here.